Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.68 |
| ▸ | DPP4 | P27487 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.68 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.68 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.68 |
| ▸ | GAPDH | P04406 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.68 |
| ▸ | STAT6 | P42226 | 1/20 | 0.68 |
| ▸ | PI4KA | P42356 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.68 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.68 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.68 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.68 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28991007 | 1.00 | ADORA3 (0.68) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL22333908 | 1.00 | ADORA3 (0.68) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL28569675 | 1.00 | ADORA3 (0.68) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL1061068 | 1.00 | ADORA3 (0.68) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL1061070 | 1.00 | ADORA3 (0.68) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL20138905 | 0.92 | ADORA3 (0.68) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL24371378 | 0.91 | ADORA3 (0.67) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL21999229 | 0.89 | AHCY (0.56) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL2227288 | 0.89 | ADORA1 (0.53) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL14916257 | 0.89 | ADORA1 (0.53) | ADORA3ADORA1DPP4MEN1SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3963087-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | Illumina Inc (US) | 2022-03-09 | — | — | EP | claimed |
| US-12582718-B2 | Integrin targeting ligands and uses thereof | Arrowhead Pharmaceuticals, Inc. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3784267-B1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ARROWHEAD PHARMACEUTICALS INC (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4594520-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2025-08-06 | — | — | EP | disclosed |
| US-12221610-B2 | RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2025-02-11 | — | — | US | disclosed |
| CN-119326905-A | GalNAc-oligonucleotide conjugate for delivery to liver and preparation method thereof | 第一三共株式会社 | 2025-01-21 | — | — | CN | disclosed |
| CN-118994152-A | Integrin targeting ligands and uses thereof | 箭头药业股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118891366-A | SiRNA inhibiting expression of transferrin receptor 2 | 第一三共株式会社 | 2024-11-01 | — | — | CN | disclosed |
| CN-118871585-A | Chemically-modified oligonucleotides with RNAi activity | 第一三共株式会社 | 2024-10-29 | — | — | CN | disclosed |
| EP-4435000-A2 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | Arrowhead Pharmaceuticals, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-114616332-B | GalNAc-oligonucleotide conjugate for delivery to liver and preparation method thereof | 第一三共株式会社 | 2024-09-20 | — | — | CN | disclosed |
| CN-112074290-B | Integrin targeting ligands and uses thereof | 箭头药业股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-3784269-B1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ARROWHEAD PHARMACEUTICALS INC (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-110249050-B | Library of non-tag encoded compounds | 南纳治疗有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-115997016-A | Composition comprising nucleic acid nanoparticles having modular functional groups | 西克斯福德生物科学有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4143316-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022165386-A1 | LNP AND LMP DELIVERY OF ANTIVIRAL NUCLEOTIDE 5'-PHOSPHATES | VIRBIS LLC (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-06-30 | — | — | US | disclosed |
| CN-114616332-A | GalNAc-oligonucleotide conjugates for delivery to liver and methods of making the same | 第一三共株式会社 | 2022-06-10 | — | — | CN | disclosed |
| EP-3963087-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | Illumina Inc (US) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | EPAS1, HIF1AN, HIF1A | ADORA3 1264/4885ADORA1 1961/4885DPP4 4839/4885 |
| US-12582718-B2 | Integrin targeting ligands and uses thereof | ITGAV, ITGA5, ITGB3 | ADORA3 1350/4885ADORA1 2323/4885DPP4 4768/4885 |
| US-12221610-B2 | RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use | EPAS1, HIF1AN, HIF1A | ADORA3 1264/4885ADORA1 1961/4885DPP4 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.